新鳳鳴(603225.SH):實控人方面再減持“鳳21轉債”250萬張
格隆匯12月23日丨新鳳鳴(603225.SH)公佈,2021年12月23日,公司分別接到實際控制人莊奎龍和中聚投資的通知,獲悉2021年12月13日-12月23日期間,莊奎龍通過上交所交易系統減持鳳21轉債累計249.5萬張,佔發行總量的9.98%;中聚投資通過上交所交易系統減持鳳21轉債5000張,佔發行總量的0.02%,莊奎龍和中聚投資合計減持鳳21轉債250萬張,佔發行總量的10%。
公司控股股東新鳳鳴控股及其一致行動人現仍合計持有鳳21轉債1076.885萬張,佔發行總量的43.08%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.